BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| Previous Close | 57.29 |
| Open | 57.93 |
| Bid | 56.18 x 800 |
| Ask | 56.40 x 1000 |
| Day's Range | 55.08 - 57.93 |
| 52 Week Range | 34.06 - 67.86 |
| Volume | 167,370 |
| Avg. Volume | 675,351 |
| Market Cap | 2.98B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.52 |
| Earnings Date | Oct 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 77.50 |
- TipRanks
3 Monster Growth Stocks That Can Rip Higher in 2020
Growth is the name of the game, of course; it’s the surest way for investors to get the returns they demand. And from a growth perspective, last year was a banner year. The three main indexes – the Dow Jones, the S&P 500, and NASDAQ – all finished the year with strong gains, ranging from 22% on the Dow to the NASDAQ’s 35%.We’re seeing that brisk growth continue this month, as the indexes are starting 2020 with gains between 2.8% and 4.6%. Even with some obvious headwinds brewing – the chaos of a U.S. presidential election year with a deeply polarized electorate –for now it looks like the markets are going to keep on trucking.We all know that past performance won’t guarantee future results. Still, the best place to start looking for tomorrow’s high-growth stocks is among yesterday’s winners. We’ve found three stocks that ended 2019 with hefty gains and put them side-by-side in the Stock Comparison tool from TipRanks. Here are the results. MasTec, Inc. (MTZ)We’ll start in the heavy industry sector, with a Florida-based leader in oil and gas, engineering, and construction. MasTec has been a fixture of the construction sector for over 20 years, and today is a $4.9 billion giant. Despite a slight slip in share prices during December, MTZ finished 2019 with an impressive overall appreciation of 57%.The impressive share gains are bolstered by a strong financial performance. MTZ last reported earnings at the beginning of November, and easily beat the EPS forecasts and the year-ago numbers. For revenue, MTZ reported $2.02 billion, which missed the forecast but was still up 2% year-over-year. The EPS number was better; at $1.73 it beat the estimate by 6% and the year-over-year number by 30%. Q3 was the fourth quarter in a row that MTZ beat the earnings forecast.Deutsche Bank analyst Chad Dillard is bullish on MTZ, seeing the company as well-positioned to continue its growth run. He writes, “Similar to 2Q, the earnings outperformance was rooted in oil and gas profitability, with segment margins ~530bps ahead of plan. Importantly, the company provided encouraging commentary on 2020, targeting low-double-digit sales growth… we remain constructive on shares, as the company is well-positioned to drive meaningful growth across its end-markets in ’20 and has continued a trend of outperforming expectations, not to be taken for granted in a challenging macro environment.”Dillard gives this stock a Buy rating with a price target of $77, suggesting strong continued gains, approaching 21% in the coming months. (To watch Dillard’s track record, click here)Overall, MTZ shares get a Strong Buy from the analyst consensus, based on 11 ratings, including no fewer than 10 Buys. Shares are selling for $63.75, and the average price target of $76.45 implies an upside potential of 20%. (See MasTec stock analysis on TipRanks) Biohaven Pharmaceutical Holding Company, Ltd. (BHVN)Our second pick today is a clinical-stage biotech. It’s common for biotech companies to operate at an earnings loss – they inhabit a niche with enormous overhead and exceedingly long lead times for new products. However, when new products do hit the market, new clinical trials start, or rumors spread of buyout possibilities, it’s not uncommon to see the shares spike. Biohaven has been the subject of such rumors since last spring, and despite high volatility, ended 2019 with a 48% gain.The company focuses its research mainly on drugs to treat migraines. This is a highly profitable space, but it does require a large salesforce right at the start. That need fed rumors that Biohaven was attracting buyers – rumors which turned out to be false. The company did, however, put out a secondary stock issue to raise capital, a move that raised over $322 million in new capital, despite temporarily depressing the share price. Gains so far in January have been modest, at nearly 3%.The company has excellent prospects moving forward, too, as its Rimegepant drug has recently shown positive Phase 3 trial results. Rimegepant is Biohaven’s lead product candidate, and a positive late-phase trial result will help bolster its approval application.Piper Sandler analyst Tyler Van Buren looks at Rimegepant through a broader lens, and sees general market reasons for a bullish stance on both the drug and the company. He notes that two competitors – Allergan and AbbVie – have received approval for a new drug in the same class as Rimegepant. The approval did not contain a warning about liver toxicity, and Van Buren sees this as a good sign for the drug class. He writes, “[T]his clearly bodes very well for the class as a whole and Biohaven's rimegepant, which had even cleaner safety and tolerability data.”Van Buren set a $100 price target on BHVN to back his Buy rating. That target indicates an impressive 79% upside potential. (To watch Van Buren’s track record, click here)Biohaven holds a Strong Buy consensus rating from the analysts, and it is unanimous. The rating is based on 7 Buys set in the last three months. The $78 average price target suggests an upside growth potential of 39% in the next 12 months. (See Biohaven stock analysis on TipRanks) Repay Holdings Corporation (RPAY)The final stock on today’s list presents an interesting case. Repay is holding company whose subsidiaries operate in the financial sector, primarily as fintech and payment processing providers. The company did not actually trade through the first half of 2019, as it was engaged in merger activity, joining with acquisition company Thunder Bridge.The transaction completed in early summer, and the company announced August 2 that RPAY shares had been reinstated on the NASDAQ index. Between the last week in July, when RPAY shares resumed active trading, and December 31, the stock showed a steady gain, finishing the year up 25%. RPAY has kept the pace in January, gaining another 9% so far this month.Repay reported Q3 earnings of 18 cents per share in November. That number was based on $19.4 million in gross profit, a 39% year-over-year gain. The company posted a total card payment volume of $2.6 billion, up 40% from the year before. Clearly, Repay’s merger activity and temporary halt in trading did not harm the company’s business.5-star analyst Mark Palmer, of BTIG, agrees, writing of the stock, “[S]hares of RPAY have appreciated by almost 41% in just over five months, we believe the stock still has ample upside, especially when considering the potential impact of a couple of acquisitions executed during 2H19 that provided the company with its own back-end payment processing platform and added the B2B payment vertical to its mix.”Palmer’s $20 price target on RPAY is in-line with his confidence in the stock – it implies an upside of 25% to the shares and backs up his Buy rating. (To watch Palmer’s track record, click here)RPAY also has a unanimous Strong Buy consensus rating, based on 5 Buys given in the past month. The average price target, $19, indicates room for a 19% upside from the current trading price of $15.97. (See Repay stock-price forecast on TipRanks)
- Insider Monkey
Hedge Fund Ardsley Partners’ Top Stock Picks
Ardsley Partners was founded back in 1987 by Philip Hempleman, who is the fund’s current Managing Partner, Chief Investment Officer, and Portfolio Manager. He holds a B.A. degree from Indiana University and an M.B.A. degree from New York University. Prior to launching Ardsley Partners, Mr Hempleman gained rich experience working in various hedge funds and […]
- Insider Monkey
How Did Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Compare Against Hedge Fund Darlings in 2019?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged in 2019. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 57%. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. That's why we weren't […]
- Zacks
Options Traders Expect Huge Moves in Biohaven (BHVN) Stock
Investors need to pay close attention to Biohaven (BHVN) stock based on the movements in the options market lately.
- PR Newswire
Kleo Pharmaceuticals to Present at Biotech Showcase 2020
Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that its Chief Executive Officer Doug Manion, MD, will present at Biotech Showcase 2020, to be held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco.
- PR Newswire
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from its randomized, dose ranging, placebo controlled, pivotal Phase 2/3 clinical trial (BHV3500-201; NCT03872453) evaluating the efficacy and tolerability of intranasal vazegepant 5, 10 and 20 mg versus placebo in 1,673 patients for the acute treatment of migraine. Vazegepant 10 and 20 mg was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS, photophobia, phonophobia or nausea) at 2 hours using a single dose (Table 1). The benefits of vazegepant were durable and sustained without rescue medication through 48 hours (nominal p < 0.05), including: sustained pain freedom 2 to 24 hours (5, 10 and 20 mg); sustained pain freedom 2 to 48 hours (5, 10 and 20 mg); sustained pain relief 2 to 24 hours (5, 10 and 20 mg); and sustained pain relief 2 to 48 hours (5 and 10 mg). Additional results from this study are anticipated to be presented at upcoming scientific meetings in 2020.
- Simply Wall St.
Have Insiders Been Buying Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Shares?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Investor's Business Daily
This Biotech Says Its Alzheimer's Drug Isn't Futile — And Shares Pop
Shares of Biohaven Pharmaceutical jumped Friday after the biotech company said it will continue a pivotal study of its Alzheimer's treatment. The drug passed a futility analysis at 26 weeks.
- Reuters
UPDATE 2-Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%. This comes a day after rival Biogen Inc built a case for its Alzheimer's drug, which it had previously planned to shelve on the basis of a futility analysis that suggested the trials would not meet their goals. Biohaven's treatment, troriluzole, was reviewed by an independent data-monitoring committee, which said the treatment showed numerically greater benefit over placebo in measuring cognitive function or hippocampal volume assessed by magnetic resonance imaging.
- Benzinga
The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...
- PR Newswire
Biohaven's Troriluzole Successfully Advances Past Interim Futility Analysis In Pivotal Phase 2/3 Alzheimer's Disease Study
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced successful completion of a pre-planned interim futility analysis for the T2 Protect AD Study. This study is an ongoing Phase 2/3 clinical trial of troriluzole in Alzheimer's disease led by the Alzheimer's Disease Cooperative Study (ADCS) at the University of California San Diego School of Medicine.
- PR Newswire
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the U.S. Patent and Trademark Office
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Pat. No. 10,485,791 on November 26, 2019 relating to troriluzole.
- Insider Monkey
Do Hedge Funds Love Biohaven Pharmaceutical Holding Company Ltd. (BHVN)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
- PR Newswire
Kleo Pharmaceuticals to Present at Piper Jaffray 31st Annual Healthcare Conference
Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance the activity of biologics, announced today that its Chief Executive Officer Doug Manion, MD, will present at the Piper Jaffray 31st Annual Healthcare Conference, to be held December 3-5 at the Lotte New York Palace in New York.
- PR Newswire
Kleo Pharmaceuticals Presents Preclinical Data Supporting Development of its CD38-ARM™, a Novel Immuno-therapeutic, at American Society of Hematology (ASH) Annual Meeting
Company's Antibody Recruiting Molecules (ARMs) Demonstrated Strong Anti-Multiple Myeloma Activity In Multiple In Vivo Animal Models and Ex Vivo Against Patient Tumor Cells NEW HAVEN, Conn. , Nov. 6, 2019 ...
- PR Newswire
Biohaven Completes Enrollment In Pivotal Phase 2/3 Alzheimer's Disease Clinical Trial Of Troriluzole
NEW HAVEN, Conn., Nov. 5, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has completed enrollment in the T2 Protect AD Study, a Phase 2/3 clinical trial of troriluzole in Alzheimer's disease. "We are hopeful this study will demonstrate that troriluzole can ameliorate the symptoms of Alzheimer's disease, by reducing synaptic glutamate through a novel mechanism of action," said Howard Feldman, MD, FRCP(C), Director of the Alzheimer's Disease Cooperative Study (ADCS) and Professor of Neurosciences at the University of California San Diego School of Medicine, who is Principal Investigator of the T2 Protect AD Study.
- PR Newswire
Biohaven Statement Regarding Kleo Pharmaceuticals (Kleo): Thomas J. Lynch, Jr., MD, Appointed As Kleo Chairman Of The Board
- Biohaven was a founding investor and the company's current ownership interest in outstanding stock of Kleo is 41.9%. NEW HAVEN, Conn., Nov. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a clinical-stage biopharmaceutical company provided an update regarding the appointment of Thomas J. Lynch, Jr., MD, as Chairman of the Board at Kleo Pharmaceuticals.
- PR Newswire
Biohaven Pharmaceuticals Reports Third Quarter 2019 Financial Results And Recent Business Developments
- Announced acceptance by the United States Food and Drug Administration (FDA) of the new drug applications (NDAs) for rimegepant and expected Prescription Drug User Fee Act (PDUFA) date of the first quarter ...
- PR Newswire
Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
NEW HAVEN, Conn., Oct. 28, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurologic and neuropsychiatric diseases, today announced that it has completed enrollment in its pivotal Phase 3 clinical trial assessing the efficacy and safety of troriluzole in generalized anxiety disorder (GAD). GAD is a chronic and long-lasting disorder in which a person has uncontrollable, excessive anxiety and worry and is often associated with significant functional impairment. According to the Anxiety and Depression Association of America (ADAA), millions of Americans suffer from GAD. If not appropriately treated, GAD has a chronic course associated with significant disability and high public burden.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- PR Newswire
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
NEW HAVEN, Conn., Sept. 18, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-stage product candidates for neurological and neuropsychiatric diseases, announced today that the Company's myeloperoxidase (MPO) inhibitor, verdiperstat, has been selected as an investigational therapy in the first Amyotrophic Lateral Sclerosis (ALS) platform trial, an innovative program designed by the Sean M. Healey & AMG Center for ALS at Mass General to help accelerate a path to new and effective ALS treatments. Verdiperstat is a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of the MPO enzyme.
- PR Newswire
Biohaven Advances NOJECTION™ Migraine Platform With Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant, The First Intranasally Administered CGRP Receptor Antagonist In Development For The Acute Treatment Of Migraine
NEW HAVEN, Conn., Sept. 10, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, today announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered vazegepant (formerly BHV-3500) for the acute treatment of migraine. Vazegepant is a novel, structurally unique, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist and the second product candidate in development for the acute treatment of migraine from Biohaven's NOJECTION™ Migraine Platform.
- PR Newswire
Biohaven Presents Data Demonstrating Reduction In Migraine-Related Disability And Improvement In Patient Reported Outcomes After Oral Treatment With Rimegepant At The International Headache Conference Late Breaking Session
· Acute treatment of migraine with rimegepant, an oral CGRP-antagonist, decreased disability by approximately 41% as measured by the Migraine Disability Assessment (MIDAS) · Rimegepant treatment also demonstrated ...
- PR Newswire
Biohaven Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Business Developments
NEW HAVEN, Conn., Aug. 8, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, the "Company"), a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today reported financial results for the quarter ended June 30, 2019, and provided a review of recent accomplishments and anticipated milestones.
